Dexcom Competitive Intelligence & Landscape

The company's core products include the Dexcom G7 and Dexcom G7 15 Day CGM Systems, which offer best-in-class accuracy and send glucose numbers directly to a user's phone or receiver in real time, aiding in diabetes management [https://dexcom.com/]. Additionally, Dexcom offers the Stelo Glucose Biosensor, a non-prescription device designed for personalized diet and exercise choices, providing glucose insights without the need for fingersticks [https://dexcom.com/]. These technologies help users understand the many factors that impact their glucose and overall health [https://dexcom.com/].

Dexcom targets individuals living with diabetes, as well as those looking to personalize their diet and exercise choices for healthier habits [https://dexcom.com/]. Headquartered in San Diego, California [https://www.dexcom.com/en-gb/about-dexcom], the company has grown significantly, employing nearly 10,000 diverse and talented employees globally [https://careers.dexcom.com/careers/index]. They have been innovating and developing solutions for over 25 years, continuously pushing the boundaries of diabetes management technology [https://www.dexcom.com/en-us/about-dexcom].

For those without insurance coverage, Dexcom provides a pharmacy savings program that allows customers to save over 50% on Dexcom G7 and G6 CGM sensors and transmitters with a coupon [dexcom.com/en-us/savings-center-cgm-without-insurance]. Both the Dexcom G6 and Dexcom G7 systems are also covered by Medicare for eligible patients [dexcom.com/en-us/faqs/medicare][dexcom.com/en-us/g7-cgm-system/medicare].

The Dexcom G7 system is highlighted for its accuracy and affordability at the pharmacy, offering real-time glucose monitoring. Features include a small, comfortable sensor, painless self-application, customizable alerts, and data sharing through Dexcom Clarity. It also offers 24/7 technical support and free virtual education classes through Dexcom CARE [dexcom.com/en-us/g7/the-dexcom-difference][dexcom.com/en-us/g7-cgm-system/medicare]. The Stelo Glucose Biosensor is designed for personal glucose insights without a prescription or fingersticks, helping users personalize diet and exercise choices [dexcom.com].

Dexcom's hiring patterns indicate a strong focus on roles that support the entire product lifecycle, from conception to manufacturing. The company frequently advertises for Biomedical Engineers and Software Engineers to "Craft the future" through creativity and innovation, highlighting its investment in research and development [careers.dexcom.com/careers/index]. Additionally, positions like Manufacturing Associate and Process Sustaining Engineer are crucial for transforming blueprints into tangible products, demonstrating a robust need for skilled personnel in production and operational excellence [careers.dexcom.com/careers/index].

The company's growth strategy appears to emphasize both technological advancement and geographic expansion. In the Asia-Pacific region, for example, Dexcom is actively building its IT team in the Philippines and Malaysia, focusing on technical research, strategy, and implementation [careers.dexcom.com/careers/apac]. While specific details about recent layoffs were not found in the provided content, the consistent and diverse range of global job postings suggests a period of sustained growth and strategic hiring to support its mission of empowering individuals to take control of their health with life-changing products like the Dexcom G7 and Stelo Glucose Biosensor.

Continuing this positive trend, Dexcom reported strong results for the first quarter of 2026. Revenue for the quarter grew 15% year-over-year to $1.192 billion. U.S. revenue increased by 11%, and international revenue surged by 26% on a reported basis. The GAAP operating income for this quarter was $255.3 million, or 21.4% of revenue [https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-First-Quarter-2026-Financial-Results/default.aspx].

Looking back at 2025, Dexcom maintained robust growth across all quarters. In the second quarter of 2025, revenue grew 15% year-over-year to $1.157 billion, with GAAP operating income at $212.6 million, or 18.4% of revenue [https://investors.dexcom.com/news/news-details/2025/Dexcom-Reports-Second-Quarter-2025-Financial-Results-Updates-Full-Year-2025-Guidance-and-Announces-CEO-Succession-Plan/default.aspx]. The third quarter of 2025 saw revenue increase by 22% year-over-year to $1.209 billion, and GAAP operating income reached $242.5 million, or 20.1% of revenue [https://investors.dexcom.com/news/news-details/2025/Dexcom-Reports-Third-Quarter-2025-Financial-Results-and-Updates-Full-Year-2025-Guidance/default.aspx].

These figures highlight Dexcom's strong financial health and consistent growth in the continuous glucose monitoring market. While specific fundraising rounds, valuations, or M&A activities are not detailed in the provided sources, the company's sustained revenue growth and increasing operating income indicate a solid financial standing and market presence for its innovative biosensing technology.

For healthcare professionals, Dexcom hosts numerous webinars and provides detailed presentations on the effective use of its products, such as the Dexcom G7 Continuous Glucose Monitoring System. These resources cover setting up and utilizing the G7 App with compatible mobile devices provider.dexcom.com/education-research/clinic-resources/webinars-and-presentations. Additionally, Dexcom collaborates with connected pump providers for a series of hybrid closed-loop (HCL) webinars, offering evidence and expert advice on integrated diabetes management dexcom.com/en-ie/healthcare-professionals/education-resources/webinars.

Dexcom also maintains a strong presence at investor conferences, with management regularly presenting updates on the company's performance and strategic direction. Notable past and upcoming investor events include the Wells Fargo Healthcare Conference, the Baird Global Healthcare Conference, the J.P. Morgan Healthcare Conference investors.dexcom.com/events-and-presentations/events/event-details/2026/44th-Annual-JP-Morgan-Healthcare-Conference-2026-JKeIP1BHx_/default.aspx, and the Raymond James Institutional Investors Conference investors.dexcom.com/news/news-details/2026/Dexcom-Announces-Upcoming-Conference-Presentation/default.aspx. The company also hosts its own Dexcom Investor Day, where it shares insights and future plans investors.dexcom.com/events-and-presentations/events/event-details/2026/2026-Dexcom-Investor-Day-2026-V4oIsePr6o/default.aspx.

Furthermore, Dexcom participates in significant medical conferences, such as the ATTD, where it highlights breakthrough outcomes for people with Type 2 diabetes and showcases its product roadmap. During these events, Dexcom hosts symposia and in-booth expert-led presentations to share upcoming product features across its global portfolio investors.dexcom.com/news/news-details/2026/Dexcom-Showcases-Breakthrough-Outcomes-for-People-With-Type-2-Diabetes-and-Product-Roadmap-at-ATTD-2026/default.aspx.